These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 32072438)

  • 21. Advanced approaches of developing targeted covalent drugs.
    Gai C; Harnor SJ; Zhang S; Cano C; Zhuang C; Zhao Q
    RSC Med Chem; 2022 Dec; 13(12):1460-1475. PubMed ID: 36561076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Covalent inhibitors: an opportunity for rational target selectivity.
    Lagoutte R; Patouret R; Winssinger N
    Curr Opin Chem Biol; 2017 Aug; 39():54-63. PubMed ID: 28609675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Covalent-reversible peptide-based protease inhibitors. Design, synthesis, and clinical success stories.
    Feral A; Martin AR; Desfoux A; Amblard M; Vezenkov LL
    Amino Acids; 2023 Dec; 55(12):1775-1800. PubMed ID: 37330416
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Road Map for the Structure-Based Design of Selective Covalent HCV NS3/4A Protease Inhibitors.
    Shunmugam L; Ramharack P; Soliman MES
    Protein J; 2017 Oct; 36(5):397-406. PubMed ID: 28815420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New drug design with covalent modifiers.
    Adeniyi AA; Muthusamy R; Soliman ME
    Expert Opin Drug Discov; 2016; 11(1):79-90. PubMed ID: 26757171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systematic Analysis of Covalent and Allosteric Protein Kinase Inhibitors.
    Xerxa E; Laufkötter O; Bajorath J
    Molecules; 2023 Aug; 28(15):. PubMed ID: 37570774
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modeling covalent-modifier drugs.
    Awoonor-Williams E; Walsh AG; Rowley CN
    Biochim Biophys Acta Proteins Proteom; 2017 Nov; 1865(11 Pt B):1664-1675. PubMed ID: 28528876
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advances in covalent kinase inhibitors.
    Abdeldayem A; Raouf YS; Constantinescu SN; Moriggl R; Gunning PT
    Chem Soc Rev; 2020 May; 49(9):2617-2687. PubMed ID: 32227030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective Covalent Inhibition of "Allosteric Cys121" Distort the Binding of PTP1B Enzyme: A Novel Therapeutic Approach for Cancer Treatment.
    Khan S; Bjij I; Soliman MES
    Cell Biochem Biophys; 2019 Sep; 77(3):203-211. PubMed ID: 31446553
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Covalent drug discovery exploiting the new warheads].
    Ojida A
    Nihon Yakurigaku Zasshi; 2022; 157(5):361-365. PubMed ID: 36047154
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug discovery considerations in the development of covalent inhibitors.
    Mah R; Thomas JR; Shafer CM
    Bioorg Med Chem Lett; 2014 Jan; 24(1):33-9. PubMed ID: 24314671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting biomolecules with reversible covalent chemistry.
    Bandyopadhyay A; Gao J
    Curr Opin Chem Biol; 2016 Oct; 34():110-116. PubMed ID: 27599186
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Covalent Inhibition in Drug Discovery.
    Ghosh AK; Samanta I; Mondal A; Liu WR
    ChemMedChem; 2019 May; 14(9):889-906. PubMed ID: 30816012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Fast Ab Initio Predictor Tool for Covalent Reactivity Estimation of Acrylamides.
    Palazzesi F; Grundl MA; Pautsch A; Weber A; Tautermann CS
    J Chem Inf Model; 2019 Aug; 59(8):3565-3571. PubMed ID: 31246457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reactive-cysteine profiling for drug discovery.
    Maurais AJ; Weerapana E
    Curr Opin Chem Biol; 2019 Jun; 50():29-36. PubMed ID: 30897495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Designing Irreversible Inhibitors--Worth the Effort?
    González-Bello C
    ChemMedChem; 2016 Jan; 11(1):22-30. PubMed ID: 26593241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Application of Dually Activated Michael Acceptor to the Rational Design of Reversible Covalent Inhibitor for Enterovirus 71 3C Protease.
    Ma Y; Li L; He S; Shang C; Sun Y; Liu N; Meek TD; Wang Y; Shang L
    J Med Chem; 2019 Jul; 62(13):6146-6162. PubMed ID: 31184893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent progress in covalent warheads for in vivo targeting of endogenous proteins.
    Shindo N; Ojida A
    Bioorg Med Chem; 2021 Oct; 47():116386. PubMed ID: 34509863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure-based design of targeted covalent inhibitors.
    Lonsdale R; Ward RA
    Chem Soc Rev; 2018 Jun; 47(11):3816-3830. PubMed ID: 29620097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New Electrophiles and Strategies for Mechanism-Based and Targeted Covalent Inhibitor Design.
    Ray S; Murkin AS
    Biochemistry; 2019 Dec; 58(52):5234-5244. PubMed ID: 30990686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.